Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma.

Abstract excerpt

Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in non-small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib. Cancer patients harboring activating EGFR mutations benefit from first-line TKI therapy. Yet 10% of patients present a primary TKI resistance, while 50% of the others...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Neoplasms
• Share to Mutation
• Share to Antineoplastic Agents